Novogen Regains Compliance with Nasdaq Listing Rules

Novogen Limited NVGN - In addition to the listing of its ordinary shares on the Australian Stock Exchange, the Company has an American Depository Receipt program with the ADRs listed on the Nasdaq Capital Market. The Company had previously announced to the market on 25 July, 2011 that it had received a notice from Nasdaq advising that it was no longer in compliance with the Nasdaq listing requirements for its ADR program and allowing 180 days in which to correct the non-compliance. On 18 January, 2012 the Company received confirmation from Nasdaq that for the ten consecutive business days, from 3 January, 2012 to 17 January, 2012, the closing bid price of the Company's ADRs had been at US$1.00 or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed. This notification from the Nasdaq Stock Market has no bearing on the ASX listing.